{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:10:30Z","timestamp":1773900630704,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.canlet.2010.05.016","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T04:41:09Z","timestamp":1276836069000},"page":"231-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-\u03b1"],"prefix":"10.1016","volume":"297","author":[{"family":"Basappa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sengottuvelan","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandagirikoppal V.","family":"Kavitha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Purushothaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kottayath G.","family":"Nevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanchugarakoppal S.","family":"Rangappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2010.05.016_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/02841868909092250","article-title":"Interactions between anticancer drugs and other clinically used pharmaceuticals. A review","volume":"28","author":"Henriksson","year":"1989","journal-title":"Acta Oncol."},{"key":"10.1016\/j.canlet.2010.05.016_bib2","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1021\/bi00306a008","article-title":"Mechanism of inactivation of chymotrypsin by 5-butyl-3H-1,3-oxazine-2,6-dione","volume":"23","author":"Weidmann","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2010.05.016_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.7164\/antibiotics.25.44","article-title":"Minimycin, a new antibiotic","volume":"25","author":"Kusakabe","year":"1972","journal-title":"J. Antibiot."},{"key":"10.1016\/j.canlet.2010.05.016_bib4","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1021\/ja00388a053","article-title":"New class of serine protease inactivators based on isatoic anhydride","volume":"104","author":"Moorman","year":"1982","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2010.05.016_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9440(10)64362-3","article-title":"Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas","volume":"160","author":"Mundhenke","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2010.05.016_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI200113738","article-title":"Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena","volume":"108","author":"Iozzo","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2010.05.016_bib7","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/bi050241p","article-title":"Identification of common and specific growth factor binding sites in heparan sulfate proteoglycans","volume":"44","author":"Chu","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2010.05.016_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0968-0004(91)90102-2","article-title":"Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?","volume":"16","author":"Vlodavsky","year":"1991","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2010.05.016_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/10518","article-title":"Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis","volume":"5","author":"Vlodavsky","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2010.05.016_bib10","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1073\/pnas.152070599","article-title":"Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis","volume":"99","author":"Goldshmidt","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2010.05.016_bib11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/10525","article-title":"Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis","volume":"5","author":"Hulett","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2010.05.016_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrc842","article-title":"Roles of heparan\u2013sulphate glycosaminoglycans in cancer","volume":"2","author":"Sasisekharan","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2010.05.016_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.chembiol.2004.02.015","article-title":"Novel heparan sulfate mimetic compounds as antitumor agents","volume":"11","author":"Ishida","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.canlet.2010.05.016_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1054\/bjoc.1999.1068","article-title":"Activated mesothelial cells produce heparin-binding growth factors: implications for tumor metastases","volume":"82","author":"Jayne","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2010.05.016_bib15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature07083","article-title":"Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation","volume":"454","author":"Tammela","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2010.05.016_bib16","doi-asserted-by":"crossref","first-page":"11322","DOI":"10.1074\/jbc.270.19.11322","article-title":"VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparin sulfates for efficient binding to the VEGF receptors of human melanoma cells","volume":"270","author":"Cohen","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2010.05.016_bib17","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/0008-5472.CAN-04-0811","article-title":"Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy","volume":"64","author":"Miyamoto","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib18","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/0008-5472.CAN-05-2753","article-title":"Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells","volume":"66","author":"Ramnarain","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib19","doi-asserted-by":"crossref","first-page":"9229","DOI":"10.1158\/0008-5472.CAN-07-1333","article-title":"The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus","volume":"67","author":"Kim","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1349-7006.2006.00188.x","article-title":"Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy","volume":"97","author":"Miyamoto","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2010.05.016_bib21","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/0008-5472.CAN-07-5704","article-title":"Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis","volume":"68","author":"Egberts","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib22","first-page":"4282","article-title":"Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo","volume":"62","author":"Lee","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/jnci\/57.5.1199","article-title":"Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines","volume":"57","author":"Fidler","year":"1976","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2010.05.016_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/glycob\/cwp041","article-title":"Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells","volume":"19","author":"Basappa","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.canlet.2010.05.016_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1021\/tx049721s","article-title":"Dynamic monitoring of cytotoxicity on microelectronic sensors","volume":"18","author":"Xing","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.canlet.2010.05.016_bib26","doi-asserted-by":"crossref","first-page":"42488","DOI":"10.1074\/jbc.M206510200","article-title":"Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence","volume":"277","author":"Okada","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2010.05.016_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2004.02.007","article-title":"Design and synthesis of a heparanase inhibitor with pseudodisaccharide structure","volume":"45","author":"Takahashi","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2010.05.016_bib28","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.carres.2006.04.014","article-title":"Semi-synthetic heparin derivatives: chemical modifications of heparin beyond chain length, sulfate substitution pattern and N-sulfo\/N-acetyl groups","volume":"341","author":"Fern\u00e1ndez","year":"2006","journal-title":"Carbohyd. Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.0.CO;2-L","article-title":"Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides","volume":"83","author":"Miao","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2010.05.016_bib30","first-page":"3631","article-title":"Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells","volume":"50","author":"Saiki","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1055\/s-2007-982088","article-title":"PI-88 and novel heparan sulfate mimetics inhibit angiogenesis","volume":"33","author":"Ferro","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.canlet.2010.05.016_bib32","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1016\/S0040-4020(01)00642-1","article-title":"Design and synthesis of a heparanase inhibitor with pseudodisaccharide structure","volume":"57","author":"Takahashi","year":"2001","journal-title":"Tetrahedron"},{"key":"10.1016\/j.canlet.2010.05.016_bib33","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1016\/j.bmcl.2004.03.098","article-title":"Simple and an efficient method for the synthesis of 1-[2-dimethylamino-1-(4-methoxy-phenyl)-ethyl]-cyclohexanol hydrochloride: (+\/\u2212) venlafaxine racemic mixtures","volume":"14","author":"Basappa","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2010.05.016_bib34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10870-005-5249-y","article-title":"Synthesis and molecular structure analysis of venlafaxine intermediate and its analog","volume":"35","author":"Kavitha","year":"2006","journal-title":"J. Chem. Cryst."},{"key":"10.1016\/j.canlet.2010.05.016_bib35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/asia.200800099","article-title":"Improvement of photoaffinity SPR imaging platform and determination of binding site of p62\/SQSTM1 to p38 MAP kinase","volume":"3","author":"Saito","year":"2008","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.canlet.2010.05.016_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control Release"},{"key":"10.1016\/j.canlet.2010.05.016_bib37","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/nm0997-1034","article-title":"Cell-cycle arrest versus cell death in cancer therapy","volume":"3","author":"Waldman","year":"1997","journal-title":"J. Nat. Med."},{"key":"10.1016\/j.canlet.2010.05.016_bib38","first-page":"161","article-title":"The metastatic process: basic research and clinical implications","volume":"11","author":"Chambers","year":"1999","journal-title":"Oncol. Res."},{"key":"10.1016\/j.canlet.2010.05.016_bib39","doi-asserted-by":"crossref","first-page":"18770","DOI":"10.1074\/jbc.273.30.18770","article-title":"Substrate specificity of heparanases from human hepatoma and platelets","volume":"273","author":"Pikas","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2010.05.016_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1568011053174882","article-title":"Anti-angiogenic therapy as a cancer treatment paradigm","volume":"5","author":"Dhanabal","year":"2005","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.canlet.2010.05.016_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1006314501634","article-title":"Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor","volume":"17","author":"Zhu","year":"1999","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.canlet.2010.05.016_bib42","doi-asserted-by":"crossref","first-page":"8779","DOI":"10.1158\/0008-5472.CAN-06-1382","article-title":"Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis","volume":"66","author":"Zhao","year":"2006","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510003058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510003058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:29:38Z","timestamp":1759591778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383510003058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0304383510003058"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2010.05.016","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-\u03b1","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2010.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}